A Multicenter, Double-Blind, Randomized, Placebo-Controlled Probe Study With an Additional Open-Label Control Arm to Evaluate the Safety and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine in Subjects With Chronic Hepatitis C Virus Infection.

Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Probe Study With an Additional Open-Label Control Arm to Evaluate the Safety and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine in Subjects With Chronic Hepatitis C Virus Infection.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2015

At a glance

  • Drugs Diphtheria-tetanus vaccine; V 520
  • Indications Diphtheria; HIV-1 infections; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 26 May 2010 Actual patient number (17) added as reported by ClinicalTrials.gov.
    • 26 May 2010 Actual end date (MaY 2010) added as reported by ClinicalTrials.gov.
    • 26 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top